The knowledge about the quality of samples and associated clinical data in biospecimen collections is a premise of clinical research. An electronic biosample register aims to facilitate the discovery of information about biosample collections in a hospital. Moreover, it might improve scientific collaboration and research quality through a shared access to harmonized sample collection description data. The aim of this paper is to present a concept of a web-based biosample register of the existing biosample collections at the Medical University of Innsbruck. A uniform description model is built based on an analysis of the sample collection data of independent sample management systems from two departments within the hospital. An extended set of attributes of the minimum dataset used by the Swedish sample collection register (MIABIS) has been applied to all biosample collections as a common description model. The results of the analysis and the data model are presented together with a first concept of a sample collection search register.

Download full-text PDF

Source

Publication Analysis

Top Keywords

biosample collections
16
sample collection
16
collections medical
8
medical university
8
university innsbruck
8
biosample register
8
description model
8
biosample
6
register
5
collections
5

Similar Publications

Telomerase is reactivated by genomic TERT rearrangements in ~30% of diagnosed high-risk neuroblastomas. Dismal patient prognosis results if the RAS/MAPK/ALK signaling transduction network also harbors mutations. We present a liquid biopsy-based monitoring strategy for this particularly vulnerable pediatric patient subgroup, for whom real-time molecular diagnostic tools are limited to date.

View Article and Find Full Text PDF

Background: In a world confronted with new and connected challenges, novel strategies are needed to help children and adults achieve their full potential, to predict, prevent and treat disease, and to achieve equity in services and outcomes. Australia's Generation Victoria (GenV) cohorts are designed for multi-pronged discovery (what could improve outcomes?) and intervention research (what actually works, how much and for whom?). Here, we describe the key features of its protocol.

View Article and Find Full Text PDF

Background & objectives Biobanks are crucial for biomedical research, enabling new treatments and medical advancements. The biobank at the Madras Diabetes Research Foundation (MDRF) aims to gather, process, store, and distribute biospecimens to assist scientific studies. Methods This article details the profile of two cohorts: the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study and the Registry of people with diabetes in India with young age at onset (ICMR-YDR).

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) treatment have shown high efficacy for about 15 cancer types. However, this therapy is only effective in 20-30% of cancer patients. Thus, the precise biomarkers of ICI response are an urgent need.

View Article and Find Full Text PDF

Deployment of a Machine Learning Algorithm in a Real-World Cohort for Quality Control Monitoring of Human Epidermal Growth Factor-2-Stained Clinical Specimens in Breast Cancer.

Arch Pathol Lab Med

December 2024

From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California.

Context.—: Precise determination of biomarker status is necessary for clinical trial enrollment and endpoint analyses, as well as for optimal treatment determination in real-world practice. However, variabilities may be introduced into this process due to the processing of clinical specimens by different laboratories and assessment by distinct pathologists.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!